We found that the clinical phenotype associated with BRD4 haploinsufficiency overlapped with that of Cornelia de Lange syndrome (CdLS), which is most often caused by mutation of NIPBL. More typical CdLS was observed with a de novo BRD4 missense variant, which retained the ability to coimmunoprecipitate with NIPBL, but bound poorly to acetylated histones. BRD4 and NIPBL displayed correlated binding at super-enhancers and appeared to co-regulate developmental gene expression.
1
. A critical role for cohesin in superenhancer function has been recently reported 2 . Acute depletion of cohesin results in disruption of higher-order chromatin structure and disordered transcription of genes predicted to be under superenhancer control. The most widely studied human cohesinopathy is CdLS, a severe multisystem neurodevelopmental disorder that is associated with a generalized deregulation of developmental genes 3, 4 . Typical CdLS is caused by heterozygous or mosaic loss-of-function (LOF) mutations in the gene encoding NIPBL. NIPBL is recruited to sites of double-strand breaks in DNA 5 and functions as a transcriptional activator 6 , but it is best known for its role in loading the cohesin complex onto DNA and is required for cohesin-mediated loop extrusion and formation of topologically associating domains [7] [8] [9] . Causative mutations in the genes encoding the core components of the cohesin ring (SMC1A, SMC3 and RAD21) [10] [11] [12] and the SMC3 deacetylase HDAC8 13 have been identified in CdLS-like conditions. However, individuals with de novo mutations in the genes encoding the chromatin-associated/modifying proteins ANKRD11 14, 15 , KMT2A 4 and AFF4 16 , which have no known association with cohesin, can also present with CdLS-like disease.
To identify previously unknown disease-associated loci, we studied 92 individuals with CdLS in whom no plausibly diagnostic variants could be identified in the known causative genes. In this group, we identified two (2 of 92, 2.2%) individuals with de novo mutations affecting BRD4. Supplementary Fig. 5 ). Subsequently, two affected individuals who were not part of the original cohort were identified with de novo frameshift mutations in BRD4. The first of these was identified via ongoing screening of individuals with CdLS-like disorders (CDL038: NM_058243.2:c.1224d elinsCA, p.(Glu408Aspfs*4); Fig. 1b ). The second indel variant was discovered through analysis of trio whole-exome sequencing data generated by the Deciphering Developmental Disorders study 17 (DDD study; DECIPHER 264293: NM_058243.2:c.691del, p.(Asp231Thrfs*9); Fig. 1b ). The latter individual was recruited to the DDD study on the basis of intellectual disability, mild short stature and a ventricular septal defect, but was not suspected of having CdLS (Supplementary Table 1 ). We reviewed the phenotypes for seven reported individuals with heterozygous multigenic deletions encompassing BRD4 and found a significant phenotypic overlap with CdLS ( Supplementary Fig. 3 and Supplementary Table 1) , with at least two of the seven individuals with deletions fulfilling the established CdLS diagnostic criteria 18 . Taken together, these data support BRD4 haploinsufficiency as the likely genetic mechanism for the CdLS-like phenotype.
It has been reported that mice carrying heterozygous LOF mutations in Brd4 show marked early-postnatal mortality, severe prenatal-onset growth failure, abnormalities of the craniofacial skeleton and reduced body fat 19 , all of which are features common in CdLS. Brd4-homozygous-null embryos die soon after implantation. Heterozygous LOF mutations in only 12 other non-imprinted autosomal mouse genes have both postnatal lethality and postnatal growth retardation recorded as features in the Mouse Genome Informatics database (MGI), with one of these being Nipbl 20 ( Supplementary Fig. 4a-c ). Of the 13 mouse genes showing haploinsufficiency, 4 have been implicated in super-enhancer function (Brd4, Nipbl, Chd7 and Crebbp) 1, 21 ( Supplementary Fig. 4e ). BRD4 is a member of the bromodomain and extraterminal domain (BET) protein family with tandem bromodomains that 'read' acetylated lysines on chromatin. BRD4 binds to hyperacetylated genomic regions that encompass promoters and enhancers, and BRD4 levels are particularly high at super-enhancers 22 . BRD4 regulates transcription elongation by paused RNA polymerase II (Pol II) via mediating the release of CDK9 activity, which results in the phosphorylation of Ser2 of the Pol II C-terminal domain. Tyr430, the residue substituted in individual 3049 with the more typical CdLS phenotype (Fig. 1b) , lies in the third alpha helix (α B ) of the BD2 domain of BRD4, close to the recognition site that mediates binding to acetylated lysine 23 . p.Tyr430Cys (Y430C) is a nonconservative amino acid substitution that could plausibly impair the binding of BRD4 to acetylated lysine. A tagged BRD4 BD2 domain containing the Y430C substitution showed reduced binding to acetylated histone peptides in vitro as compared with wild-type BD1 and BD2 domains (Fig. 2a) . In mouse BRD4, the 'human-equivalent' missense variant would be p.Tyr431Cys; the difference in amino acid numbering is the result of an extra proline in the polyproline repeat (position 215-217 in the human protein; Supplementary Fig. 6 ).
BRD4 interacts with NIPBL and
To avoid confusion, we use Brd4 Y430C as the mouse variant designation; we introduced this variant onto both alleles (Brd4 Y430C/Y430C ) in mouse embryonic stem cell (mESC) lines using Cas9-induced homology-directed repair (HDR). BRD4 immunoprecipitation (IP) in Brd4 Y430C/Y430C mESCs revealed impaired binding to acetylated histones (H3K9ac and H3K27ac) ( Fig. 2b and Supplementary Fig. 18 ).
Label-free quantitative (LFQ) mass spectrometry (MS) following IP was performed using two different BRD4 antibodies on lysates from Brd4 Y430C/Y430C and wild-type mESCs (Supplementary Table 4 ). This detected 1,082 proteins present in BRD4 immunoprecipitates from both cell lines, 90 of which were absent in all of the IgG controls (Fig. 2c ). Of these, BRD4 was the top hit, with 3 of the remaining 89 proteins being NIPBL, RAD21 (core cohesin ring component) and ESCO2 (SMC3 acetylase) ( Fig. 2d and Supplementary Fig. 7 ). Other subunits of cohesin (SMC1A, SMC3, STAG2, PDS5A and PDS5B) also showed evidence of enrichment ( Supplementary Fig. 8 ). The association of BRD4 with NIPBL was replicated using LFQ MS on an independent Brd4 Y430C/Y430C mESC line created using the same genome-editing protocol. Reciprocal IPs using antibodies to NIPBL and SMC3 confirmed BRD4 interaction with both NIPBL and the core cohesin ring (Fig. 2e and Supplementary Figs. 9 and 20) . In mESCs, BRD4
Y430C showed a similar level of NIPBL association as wild-type BRD4, suggesting that this interaction is unlikely to be mediated by co-binding to acetylated chromatin (Fig. 2e and Supplementary Figs. 9, 19 and 20) .
To further assess the functional consequences of the BRD4 missense variant, we generated F 0 mouse embryos following zygote injections of reagents to induce Cas9-mediated HDR. As judged from digital sectioning in optical projection tomography, the morphologies of Brd4 Y430C/+ and Brd4 Y430C/Y430C F 0 mouse embryos were indistinguishable from that of wild-type embryos. We also generated apparently non-mosaic F 0 embryos homozygous for a 15-bp in-frame deletion (NM_020508.4:c.1288_1302del, p.(Cys430_Asn434del); Supplementary Fig. 10 ), designated Brd4
C429_N433del/C429_N433del to maintain consistency with human nomenclature, which showed significant growth restriction at 13.5 days post coitum (d.p.c.) as their only obvious abnormal phenotype ( Supplementary Fig. 11 ). We derived mouse embryonic fibroblasts (MEFs) from F 0 Brd4
Brd4
C429_N433del/C429_N433del and control mouse embryos at 13. Fig. 12 ) using an antibody raised against a peptide representing amino acids 1,312-1,362 in the mature protein. The apparent null status of these cells may be the result of rapid degradation of the abnormal protein or an artefact resulting from a change in the epitope. The latter may also explain the survival of these homozygous embryos past implantation.
BRD4 ChIP in Brd4 Y430C/Y430C MEFs showed reduced binding of the variant BRD4 to the promoters and super-enhancers of known BRD4 targets compared with wild-type MEFs (Fig. 2f) . To assess regions of common binding, we performed BRD4 ChIP-seq on wild-type mESCs and compared these findings to publicly accessible NIPBL and BRD4 ChIP-seq data from mouse (Supplementary Fig. 13 ) and human ( Supplementary Fig. 14) ESCs. We used the intersection of the BRD4-bound and NIPBL-bound genomic intervals from the ChIP-seq data to create a set of high-confidence shared binding sites. By comparing different functional genomic Y430C/Y430C mESCs. Input is 1% of mESC nuclear extract. Antibodies detected BRD4, H3K9ac, H3K27ac, H4K8ac and H3. c, Heat map of the label-free mass spectrometry quantitative output values (average of triplicates) assigned to each protein following immunoprecipitation in mESCs with wild-type BRD4 (WT) and BRD4-Y430C using IgG-only control or Abcam/Bethyl antibody against BRD4. d, Plot of the log Andromeda scores assigned to the 90 proteins that were absent in the IgG controls and present in both cell lines using both BRD4 antibodies. Horizontal scatter aids the visibility of each open circle and has no data correlate. e, Cropped immunoblots of reciprocal immunoprecipitations using BRD4 and NIPBL antibodies in mESCs with wild-type Brd4 and Brd4 Y430C/Y430C mESCs. Antibodies detected BRD4, NIPBL and SOX2. f, Percentage input bound for BRD4 ChIP-qPCR across genomic regions in MEFs with wild-type BRD4 and BRD4-Y430C mutant (error bars, s.e.m. from n = 2 biological replicates). g, Forest plots of the log 2 odds ratios with confidence intervals (CIs) of different functional genomic categories in intersecting regions from BRD4 and NIPBL mESC ChIP. h, UCSC Genome Browser graphic showing colocalization of BRD4 and NIPBL ChIP-seq peaks with the super-enhancer (blue bar) at the Klf4 locus. H3K27ac, H3K4me1, H3K122ac and super-enhancer tracks were previously published.
categories, we found that mESC super-enhancers showed the highest level of enrichment, with heterochromatin being the least enriched (Fig. 2g,h and Supplementary Fig. 15 ). To look for any common functional effect on gene expression, we then generated array-based transcriptome data from control, Brd4
and Nipbl +/− MEFs ( Supplementary Fig. 16 ). Of the > 18,000 genes probed on the microarray, 3,049 had a transcription start site within 1 Mb of a defined MEF super-enhancer (Super Enhancer Archive). These super-enhancer-associated genes showed significantly higher levels of differential expression in both Brd4-mutant (P = 0.002) and Nipbl-mutant (P = 0.006) cells compared with genes that were not super-enhancer associated. There was also a significant overlap in the specific genes that showed differential expression in both BRD4-and NIPBL-mutant MEFs (Supplementary Fig. 17 ).
CdLS can be considered to be a transcriptomopathy 4 , presumed to result from a loss of cohesin-dependent chromatin loops or a cohesin-independent NIPBL-mediated transcriptional activity 6 . Our identification of de novo heterozygous LOF mutations in BRD4 in patients with a CdLS-like disorder, together with our functional genomic data, suggests that CdLS may be more specifically defined as a disorder of super-enhancer function. Delineation of any direct or indirect physical interaction and/or functional co-dependency of BRD4 with NIPBL can now reasonably become a topic of investigation.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0042-y. Fig. 1 ) are part of a larger cohort of patients with a diagnosis of CdLS or possible CdLS, referred by experienced clinical geneticists or pediatricians to the MRC Human Genetics Unit for research genetic analysis 14 . The third individual (CDL038) was referred to the DNA Diagnostic Laboratory in NHS Lothian with a CdLS-like disorder. The final affected individual (264293) was identified using the trio whole-exome sequence data generated by the DDD study. Written consent was obtained from the parents and/or guardians of the affected individuals both for participation in the study and, seperately, for use of the clinical photographs in this report.
Brief CommuniCation
Array comparative genomic hybridization. Array comparative genomic hybridization was performed using the NimbleGen 135k microarray platform (Roche NimbleGen) as described previously 24 . Results were compared with the Database of Genomic Variants, and polymorphic copy number variants (CNVs) were excluded.
Droplet digital PCR.
A pair of oligonucleotide primers and the matching 5′ FAMlabeled Universal Probe Library (UPL) probe (#25) (Roche) were designed to target coding exon 17 of the BRD4 gene using ProbeFinder software version 2.50 (Roche).
Each 20-µ l ddPCR reaction consisted of 40 ng of genomic DNA, 1× ddPCR SuperMix for probes (no dUTP) (Bio-Rad), forward and reverse primers at 1 µ M each, UPL probe #25 at 250 nM and 1× 5′ VIC-labeled RNase P TaqMan Copy Number Reference assay (Thermo Fisher Scientific). Droplet generation using the QX200 droplet generator (Bio-Rad) followed by amplification (95 °C for 10 min, 40 cycles of 94 °C for 30 s and 57 °C for 60 s, and a final incubation at 95 °C for 10 min) was performed per the manufacturer's instructions (Bio-Rad). Following completion of the PCR, plates were read using the QX200 droplet reader (Bio-Rad). Analysis of droplet counts, amplitudes and DNA copy number were performed with QuantaSoft software (Bio-Rad) for channel 1 (FAM) and channel 2 (VIC).
Mutation analysis by DDD trio exome sequencing, ion AmpliSeq PCR-Ion PGM and Sanger sequencing. As part of DDD Complementary Analysis Protocol 35, VCF files on the first 4,293 trios with whole-exome sequence data were searched for candidate de novo mutations in BRD4. Only one possible de novo disruptive variant was identified in BRD4. This variant was validated as de novo using the approach mentioned below. No other plausible cause for the developmental disorder was apparent on trio-based whole-exome analysis.
An AmpliSeq panel encompassing the coding exons of BRD4 and nine other candidate genes was designed using the Ion AmpliSeq Designer tool (Life Technologies, IAD41056). Library preparation and sequencing on the Ion PGM platform (Life Technologies), followed by sequence alignment and variant calling on software NextGENe version 2.3.3 (Soft Genetics), were performed as described previously 14 . A total of 92 individuals were screened, who had previously scored as negative for mutations in NIPBL, SMC1A, SMC3, HDAC8 and RAD21 and largescale genomic deletions/duplications. The same panel also applied to subsequent clinical referrals to the NHS DNA diagnostic laboratory in Edinburgh was used to identify one further de novo heterozygous LOF mutation in an individual who had a CdLS-like phenotype.
Any significant variants were confirmed by Sanger sequencing and analyzed using Mutation Surveyor software version 3.30, as described previously 24 . The BRD4 sequence identifier NC_000019.10 was used in the analysis. Sequence variant nomenclature is reported according to the BRD4 transcript variant NM_058243. Primer sequences and PCR conditions are available upon request.
Plasmids, expression and purification of proteins. Human BRD4 BD1 and BD2 plasmids were kindly gifted by S. Knapp (Nuffield Department of Clinical Medicine). Proteins were expressed and purified at the Edinburgh Protein Production Facility as described previously 25 .
Site-directed mutagenesis. The point mutation c.1289A>G, predicted to result in the protein variant p.Tyr430Cys (Y430C), was introduced into the BRD4-BD2 and FLAG-mBRD4 constructs using the QuikChange II XL Site-Directed Mutagenesis kit (Agilent Technologies) following the manufacturer's instructions. The presence of the desired mutations was confirmed by Sanger sequencing.
CRISPR-Cas9 construct design.
Guide RNA (gRNA) 1 and 2 were designed across Tyr430 using the online tool DNA 2.0. The wild-type and mutant repair templates (chr. 17: 32,220,150-32,220,271; GRCm38) were synthesized by IDT as 122-bp UltramerssODNs bearing the desired sequence change. For genome editing in mESCs, gRNAs 1 and 2 were cloned into PX461 (Addgene plasmid 48140) and PX462 (Addgene plasmid 62987), respectively. For genome editing in mouse embryos, both gRNAs were cloned into PX461 and the full gRNA template sequence was amplified from the resulting PX461 clone using universal reverse primer and T7-tagged forward primers. The gRNA PCR template was used for in vitro RNA synthesis with T7 RNA polymerase (NEB), and the RNA template was subsequently purified using RNeasy mini kit (Qiagen) purification columns. Cas9n mRNA was procured from Tebu Bioscience.
Genome editing in mESCs.
To generate mESCs carrying the p.Tyr430Cys missense variant in BRD4, 46 C cells were cotransfected with gRNAs 1 and 2 (0.5 μ g/ml) and the mutant repair template (0.5 μ g/2 ml) using Lipofectamine 3000 transfection reagent (Thermo Fisher) per the manufacturer's instructions. After 48 h, successfully transfected cells were selected first by puromycin treatment and subsequently by FACS based on GFP expression. Resulting GFP-positive and puromycin-resistant cells were plated at 5,000 cells/10 cm 2 . After 1 week, colonies were picked and plated in duplicate at 1 colony/well of a 96-well plate. Genomic DNA was extracted from the colonies and sequenced by Sanger sequencing. Wildtype clones and clones homozygous for the p.Tyr430Cys variant were expanded and frozen for later use.
Genome editing in mouse embryos and generation of mouse embryonic fibroblasts. To generate mouse embryos carrying the p.Tyr430Cys variant in BRD4, injections were performed in single-cell mouse zygotes. Injection mix contained Cas9 mRNA (50 ng/μ l), gRNAs 1 and 2 (25 ng/μ l) and each repair template DNA (75 ng/μ l). The embryos were analyzed at the 13.5 d.p.c. stage of embryonic development. MEFs were isolated from the limbs of individual embryonic day (E) 13.5 embryos by mincing in 1 ml of medium (DMEM, 10% FCS, 50 U/ml penicillin and 50 mg/ml streptomycin). Resulting suspensions were grown at 37 °C, 5% CO 2 and 3% O 2 , and non-adherent cells were removed after 24 h. MEFs from embryos with unedited Brd4 alleles, clean homozygous knock-in for p.Tyr430Cys in Brd4 (Brd4 Tyr430Cys/Tyr430Cys
) and homozygous knock-in for an in-frame deletion (Brd4 Cys430_Asn434del/Cys430_Asn434del ) alleles were used for further experimentation.
Generation of heterozygous loss-of-function Nipbl MEFs.
Mice with a floxed allele of Nipbl (a kind gift from H. Peters, University of Newcastle) were crossed with Cre745 mice (a kind gift from D.J. Kleinjan, University of Edinburgh), containing a CAGGS-Cre construct in which Cre recombinase is under the control of the chicken β -actin promoter, to excise Nipbl exon 1. Embryos were collected at 13.5 d.p.c. MEFs were isolated from the limbs of heterozygous Nipbl knockout embryos by mincing in 1 ml of medium (DMEM, 10% FCS, 50 U/ml penicillin and 50 mg/ml streptomycin). Resulting suspensions were grown at 37 °C, 5% CO 2 and 3% O 2 , and non-adherent cells were removed after 24 h.
Histone tail peptide arrays.
A modified histone peptide array (Active Motif, 13005) experiment was performed as described previously 26 . Briefly, the array was blocked in TBST buffer (10 mM Tris-HCl pH 8.3, 0.05% Tween-20, 150 mM NaCl) containing 5% nonfat dried milk at 4 °C overnight. The membrane was washed with TBST for 5 min and incubated with 10 nM purified His-tagged BRD4 BD1 or wild-type or p.Tyr430Cys (Y430C) BD2 domain, at room temperature (20-22 ºC) for 1 h in interaction buffer (100 mM (0.5 μ g/3 ml) KCl, 20 mM HEPES pH 7.5, 1 mM EDTA, 0.1 mM DTT, 10% glycerol). After washing in TBST, the membrane was incubated with mouse antibody to His (Sigma, H1029, 1:2,000 dilution in TBST) for 1 h at room temperature. The membrane was then washed three times with TBST for 10 min each at room temperature and incubated with horseradish peroxidase-conjugated anti-mouse antibody (1:10,000 in TBST) for 1 h at room temperature. The membrane was submerged in ECL developing solution (Pierce, 32209), imaged (ImageQuant, GE Healthcare), and the data were quantified using array analyzer software (Active Motif).
Nuclear extract coimmunoprecipitation. 30 × 10
6 wild-type mESCs and mESCs with p.Tyr430Cys (Y430C) BRD4 were trypsinized, pelleted and resuspended in 5 ml of ice-cold swelling buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, Complete Mini EDTA-free protease inhibitor (Roche)) for 5 min on ice. Nuclei were pelleted by centrifugation at 228g for 5 min at 4 °C. The resulting nuclear pellets were sonicated in 2 ml of RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, benzonase and Complete Mini EDTA-free protease inhibitor (Roche)), using a Bioruptor Plus sonication device (Diagenode) at 4 °C, 30 s on, 30 s off. It was noted that prolonged (1-h) exposure to the detergents in RIPA buffer affected the interactions of BRD4 as measured by mass spectrometry. Nuclear extracts were cleared by centrifugation at 13,000 r.p.m. for 10 min at 4 °C. Protein A Dynabeads (Life Technologies) were blocked before antibody coupling by washing three times with 5% BSA in PBS. Antibodies were coupled to the beads at 5 μ g/ml by rotation for 1 h at 4 °C. Equivalent nuclear protein amounts were incubated with antibody-coupled beads for 1 h at 4 °C. Beads were washed, and pulled-down proteins were analyzed by mass spectrometry or western blot. Antibodies used were as follows: BRD4 (Bethyl, A301-985A100), SMC3 (Bethyl, 0300-060 A), NIPBL (Bethyl, A301-779A) and normal rabbit IgG (Santa Cruz, sc-2027).
Western blots. For western blot analysis, beads were washed five times with RIPA buffer, and bound proteins were eluted by boiling in 1× NuPage LDS buffer (Thermo Fisher Scientific) with 1× NuPage reducing agent (Thermo Fisher Scientific) for 5 min and separated on a 3-8% Tris-acetate gel (reciprocal BRD4/ SMC3/NIPBL IPs and MEF cell lysates) or a 4-12% Bis-Tris gel (BRD4 IPs for acetylated histone binding) (Thermo Fisher Scientific). Following electrophoresis, proteins were transferred to nitrocellulose membranes (Thermo Fisher Scientific) using the iBlot 2 Dry Blotting System (Thermo Fisher Scientific) for 7 min (when probing for proteins < 250 kDa only) or to PVDF membranes by wet transfer for 90 min (when probing for proteins > 250 kDa), and membranes were incubated with primary antibodies overnight at 4 °C. Membranes were washed three times in TBST and probed with horseradish peroxidase-conjugated secondary antibody (anti-rabbit/anti-goat, 1:10,000) for 1 h at room temperature. After three more washes in TBST, membranes were incubated with Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) for 5 min and imaged (ImageQuant, GE Healthcare). Antibodies used were as follows: BRD4 (Bethyl, A301-985A100, 1:3,000), SMC3 (Bethyl, 0300-060 A, 1:1,000), H3K27ac (Genetex, GTX128944, 1:1,000), H4K8ac (Abcam, ab15823, 1:1,000), H3K9ac (Abcam, ab10812, 1:500), H3 (Abcam, ab1791, 1:5,000), NIPBL (Bethyl, A301-779A, 1:1,000), SOX2 (Abcam, ab97959, 1:1,000) and β -actin (Abcam, ab8229, 1:500).
Mass spectrometry. For analysis by mass spectrometry, beads were washed three times with Tris-saline buffer, and excess buffer was removed. IPs were digested on beads, desalted and analyzed on a Q-Exactive plus mass spectrometer as previously described 27 . Proteins were identified and quantified by MaxLFQ 28 by searching with MaxQuant version 1.5 against the Mouse proteome database (UniProt). Modifications included C carbamlylation (fixed) and M oxidation (variable). Bioinformatic analysis was performed with the Perseus software suite.
ChIP-qPCR. Primary MEFs isolated from 13.5 d.p.c. embryos were cultured for 3-4 passages in DMEM supplemented with 15% FCS, 1% penicillin-streptomycin, l-glutamine, non-essential amino acids and sodium pyruvate. Cells were harvested by trypsinizing and were fixed immediately with 1% formaldehyde (Thermo Fisher, 28906) (25 °C, 10 min) in PBS; reactions were stopped with 0.125 M glycine. ChIP was performed as described previously 29 . Briefly, cross-linked cells were resuspended in Farnham lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40, Complete Mini EDTA-free protease inhibitor (Roche)) for 30 min and centrifuged at 228 g for 5 min at 4 °C. Nuclei were resuspended in RIPA buffer (1 × PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (filtered through a 0.2-to 0.45-µ m filter unit) + Complete Mini EDTA-free protease inhibitor (Roche)) and sonicated using a Bioruptor Plus sonication device (Diagenode) at full power for 40 min (30 s on, 30 s off) to produce fragments of 100-500 bp. 3 µ g of each antibody was incubated with Protein A Dynabeads (Thermo Fisher Scientific, 10001D) in 5 mg/ml BSA in PBS on a rotating platform at 4 °C for 2 h. An arbitrary concentration of 50 µ g of chromatin was incubated with antibodybound Dynabeads in a rotating platform at 4 °C for 16 h.; the concentration of each antibody at this stage was 3 μ g/ml. Beads were washed five times (5 min each) on a rotating platform with cold LiCl wash buffer (100 mM Tris pH 7.5, 500 mM LiCl, 1% NP-40, 1% sodium deoxycholate) and one time with room-temperature TE buffer. ChIP complexes were eluted with elution buffer (1% SDS, 0.1 M NaHCO 3 ), and input and ChIP samples were incubated at 65 °C for 5 h to reverse the crosslinks. 2 µ l of RNase A (20 mg/ml) was added, and samples were incubated at 37 °C for 1 h before 2 µ l of proteinase K was added and samples were incubated for 2 h at 55 °C. DNA was purified using the QIAquick PCR Purification kit (Qiagen, 28104) and analyzed by qPCR with the primers described in Supplementary Table 2 . Antibodies used were as follows: rabbit IgG (Santa Cruz, sc-2025) and BRD4 (Bethyl, A301-985A100).
ChIP-seq. Wild-type mESCs were cultured in GMEM medium supplemented with 10% FCS, 1% penicillin-streptomycin, l-glutamine, non-essential amino acids, sodium pyruvate and 1,000 U/ml LIF. Cells were harvested by trypsinizing and were fixed immediately with 1% formaldehyde (Thermo Fisher, 28906) (25 °C, 10 min) in PBS. This reaction was quenched with 0.125 M glycine. ChIP was carried out as above. After purification, DNA was eluted in 20 μ l and libraries were prepared for ChIP and input samples as previously described 30 . Samples were sequenced at BGI (Hong Kong; 50-bp single-end reads) using the HiSeq 4000 system (Illumina).
Transcriptome analysis. RNA was extracted from Brd4
Tyr430Cys/Tyr430Cys and Nipbl heterozygous null MEFs using the RNeasy Mini kit (Qiagen) per the manufacturer's instructions. 1 μ g of RNA was hybridized to a SurePrint G3 Mouse GE 8 × 60 K microarray (Agilent, G4852A) and arrays were scanned on a NimbleGen scanner as described previously 31 . Quantile normalization and background correction (method normexp) of the microarray data were carried out using the Bioconductor package limma 32 . Gene-level expression was calculated by averaging the signal for probes that mapped to the same gene (Gene Symbols mapped to Probe identifiers obtained from GEO, GPL13912, Agilent-028005 SurePrint G3 Mouse GE 8 × 60 K Microarray). The normalized signal for technical replicate samples was averaged before differential expression analysis.
Transcriptome analysis statistics. Gene-level differential expression analysis was conducted using the Bioconductor package limma 32 . Briefly, a linear model was fitted to each gene. Then, empirical Bayes moderation was applied to the linear model fit to compute moderated t statistics, moderated F statistics and the logodds of differential expression. The Benjamini and Hochberg method was used to correct the P values for multiple testing. Genes were identified as significantly differentially expressed if the FDR q value was < 0.1.
To test whether genes (n = 3,049/19,113) with a transcription start site within 1 Mb of MEF super-enhancers were more highly ranked than other expressed genes in terms of differential expression (t statistic), we performed a mean-rank gene set test (geneSetTest, Bioconductor package limma).
A hypergeometric test was performed on the differentially expressed gene sets for Brd4 and Nipbl to determine whether differentially expressed genes were significantly enriched between the two groups.
ChIP-seq analysis. Bowtie 2 (version 2.2.6) was used to map reads to mouse (mm9) and human (hg19) genomes (options bowtie2-align-s --wrapper basic-0) 33 .
To calculate the correlation of NIPBL and BRD4 with other histone modifications (Supplementary Table 3) , the correlation of the ChIP-seq binding profiles across the genome was calculated. DeepTools (version 2.3.5) multiBamSummary was used to calculate the coverage of mapped reads in 150-bp sequential bins across the mm9/hg19 genome (options: --binSize 150 bp, --ignoreDuplicates, --black, ListFileName, --extendReads 150, --mappingquality 30) 34 . Genomic bins within blacklisted regions and chromosomes X and Y were excluded from the analysis. Genomic bins were also restricted to regions of open chromatin using DNase Ihypersensitive sites identified by the ENCODE Project 35 (Supplementary Table 3 ). The genome-wide coverage matrix was imported into R, and Pearson's R was calculated. Correlation scores were visualized as a heatmap using the R package pheatmap (options: Euclidean distance and complete clustering method).
Peak calling.
To call BRD4-and NIPBL-bound regions, we used the MACS peak caller (2.1.1). For BRD4 peaks, we used the parameters broadPeaks and an FDR cutoff of 0.1.
For NIPBL, we used the public ChIP-seq dataset for NIPBL in V6.5 (C57BL/6-129) mESCs (GSM560350) and, the accompanying whole-cell extract dataset (GSM560357) as background.
For peak calling, we used MACS with the parameters narrowPeaks and an FDR cutoff of 0.1. To perform intersections on genomic ranges, such as peaks regions, we used bedtools intersect (2.26.0) 36 . Any peaks that intersected with the mm9 genome blacklist regions or mapped to non-canonical chromosomes were removed from subsequent analysis.
Genomic region enrichment.
To determine the preference of colocalized NIPBL and BRD4 binding to specific chromatin states, we performed Fisher enrichment analysis on a chromatin state map in mESCs (ChromHMM, mm9). This state map has annotated the genome into major chromatin states, including active promoter, poised promoter, strong enhancer, poised or weak enhancer, insulator, repressed, transcribed and heterochromatin.
In addition, we looked at enrichment of colocalized NIPBL and BRD4 binding sites with super-enhancer regions found in mESC line E14 using data from SEA: Super-Enhancer Archive 37 . We used the consensus set of super-enhancer regions from two mESC E14 replicates to define super-enhancer regions 37 .
Genomic region enrichment statistics. To calculate enrichment of peaks, we used bedtools (2.26.0) Fisher tests. The Fisher's odds ratio was converted to the log 2 scale and plotted using the R forest plot package. 
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n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
